JMS strives to improve the quality of corporate management and the corporate value, in order ' To be a bridge for the people who give and seek medical care, and to bring a smile to people by contributing to a healthy and better life' under our Founding Spirit of 'For People’s Precious Life'. JMS focused on four fields of business activities such as infusion & enteral nutrition, dialysis, cardiovascular and blood transfusion and promotes product development, production and sales.
In regard to the business environment surrounding the JMS Group, for the domestic market, as a result of progress in COVID-19 countermeasures such as vaccination and the shift to a "new lifestyle" towards coexistence with COVID-19, showing a recovery trend in refraining from doctor visits and postponing non-essential surgeries and procedures. Demand is expected to continue to recover due to the deregulation of COVID-19 and other factors, including the revision of classification of COVID-19 to “Category 5” in the Infectious Diseases Act in May 2023. In overseas markets, although the situation varies depending on the country and region, there is a general recovery from the impact of COVID-19, and the shift to coexistence with COVID-19 is accelerating worldwide. Although soaring ocean freight rates calms down, soaring prices of raw materials and electricity costs based on rising crude oil prices are still putting pressure on corporate management, and the external business environment remains severe. Even under these circumstances, the outlook in medical equipment market is expected to continue to show stable growth against the background of the global advance of aging, growing health conscious, rising expectations for advanced medical care, and increased demand in emerging countries. In recent years, the trend toward medical DX has led to a demand for reducing the burden on medical staff and improving the efficiency of medical services through online medical care and the use of collected/analyzed data. As a result, it is expected that the provision of optimal solutions to meet these demands will become increasingly important in the market.
In the domestic market, sales related to the Acute Blood Purification business increased, and sales of Closed Drug Mixing/Infusion Systems, Hemodialysis Machines, and Cardiopulmonary Blood Tubing Sets were also strong. In overseas markets, the situation varies depending on the country or region, but there has been a recovery from the impact of the COVID-19, with increased sales of AVF needles and Apheresis kits, and strong sales of Blood bags.
As a result of the above, JMS recorded consolidated net sales of 63,740 million yen in this period, up by 9.6% / 5,571 million yen (year-over-year), due in part to an increase in yen equivalent value resulting from yen depreciation. Despite the effect of increase sales, the impact of soaring raw material and electricity costs, and the increase in labor costs in preparation for the recovery in demand, as well as selling expenses associated with the resumption of sales activities, resulted in an operating profit of 724 million yen, down by 26.1% (year-over-year). Due to a decrease in subsidy income and equity in earnings of affiliates, ordinary income resulted in 586 million yen, down by 47.9% (year-over-year). As a result of adding and subtracting gains on sales of investment securities, income taxes, etc., the profit attributable to owners of the parent was 281 million yen, down by 66.0% (year-over-year).